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BACKGROUND: The urokinase plasminogen activator (uPA) system is one of the best-investigated protease systems, both under
physiological and pathological conditions, including various types of cancer. However, effects of co-expression of members of the uPA
system in soft-tissue sarcoma (STS) patients at the protein level in both tumour tissue and serum have not been investigated yet.
METHODS: We examined 82 STS patients for protein levels of uPA, PAI-1and uPAR in tumour tissue and serum by ELISA.
RESULTS: A significant correlation between high antigen levels of uPA, PAI-1 or uPAR in tumour tissue, and of uPAR in serum, with
poor outcome of STS patients was found for the first time. Most strikingly, we observed an additive effect of combined uPA, PAI-1 or
uPAR levels in tumour tissue extracts with uPAR levels in serum on patients’ prognosis. High uPA/uPAR, PAI-1/uPAR and uPAR/
uPAR antigen levels in tumour tissue/serum were associated with a 5.9-fold, 5.8-fold and 6.2-fold increased risk of tumour-related
death (P¼0.003, 0.001 and 0.002, respectively) compared with those patients who displayed low levels of the respective marker
combination.
CONCLUSION: As expression of members of the uPA system in tumour tissue and serum is additively correlated with prognosis of STS
patients, our results suggest that combinations of these biomarkers can identify STS patients with a higher risk of tumour-related
death.
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The urokinase plasminogen activator (uPA) system comprises the
serine protease uPA, its receptor uPAR and two inhibitors PAI-1
and PAI-2 (Duffy, 2004). Components of the uPA system have an
important role in tumourigenesis, extracellular matrix (ECM)
degradation, angiogenesis, as well as in proliferation, migration
and adhesion of tumour cells (Duffy and Duggan, 2004; Mondino
and Blasi, 2004; Pillay et al, 2007). They are prognostic factors in
different types of cancer. For example, elevated tumour tissue levels
of uPA have prognostic impact in a variety of cancers such as breast,
colon, oesophagus, ovary and stomach cancer, high antigen levels of
uPAR are associated with poor prognosis in cancer of the breast and
colon, and elevated levels of PAI-1 are correlated with shortened
overall and/or disease-free survival in renal, ovarian and breast
cancer (Duffy and Duggan, 2004; Clark et al, 2008). Nevertheless, the
clinical finding that an enzyme inhibitor does not have a protective
function but is an indicator of worse prognosis is, at first glance,
surprising. However, apart from being a uPA inhibitor, it has been
demonstrated that PAI-1 has different, additional tumour-support-
ing functions (Duffy et al, 2008). Only one study has so far
determined the protein expression of components of the uPA
system and evaluated its impact on prognosis for soft-tissue
sarcoma (STS) patients. Increasing uPA protein levels in tumour
tissue were associated with local recurrence and metastasis in 69
STS patients (Choong et al, 1996). Up to now, however, there are no
studies that have investigated protein levels of all three components
of the uPA system in tumour tissue and serum of STS patients.
Therefore, we determined the expression of uPA, uPAR and PAI-1
on protein level in a cohort of 82 adult STS patients, and evaluated
their relationship with relevant clinicopathological parameters and
overall survival (OS). In addition, the effect of combined uPA, uPAR
and PAI-1 values in tumour tissue and serum of STS patients was
analysed.
Received 29 September 2009; revised 24 November 2009; accepted
1 December 2009; published online 5 January 2010
*Correspondence: Dr H Taubert, Department of Oral and Maxillofacial
Plastic Surgery, Faculty of Medicine, Martin-Luther-University Halle-
Wittenberg, Große Steinstrasse 19, Halle/Saale D-06097 Germany;
E-mail: helge.taubert@medizin.uni-halle.de
British Journal of Cancer (2010) 102, 731–737
& 2010 Cancer Research UK All rights reserved 0007– 0920/10 $32.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sMATERIALS AND METHODS
Patients and tumour material
This study was performed on tumour tissue samples of 82 adult
patients with histologically verified STS that have been described in
previous studies (Wu ¨rl et al, 2002). The study adhered to national
regulations on ethical issues and was approved by the local ethical
committee. All patients gave written informed consent (Department
of Surgery 1, University of Leipzig, Germany). The median age of
patients at surgery was 55.8 years (range 17–83 years). The median
follow-up time of patients was 46 months (range 2–146 months after
primary tumour resection). Tumours were staged according to the
UICC system. Relevant data on clinical parameters of the STS patients
are shown in Table 1.
Out of 82 STS patients, uPA, uPAR and PAI-1 antigen levels
could be determined in tumour tissue samples for 80 patients, and
for 79 patients in preoperative serum samples. For 77 patients,
uPA, uPAR and PAI-1 protein levels were determined in both
tumour tissue and serum.
Determination of uPA, uPAR and PAI-1 antigen by ELISA
Tissue extracts were prepared from frozen STS in the presence of
Triton X-100 (detergent extracts) as previously described (Ja ¨nicke
et al, 1994; Luther et al, 1996). Briefly, after solubilisation of
membrane-bound proteins using Tris buffer containing the non-
ionic detergent Triton X-100 (1%), cell debris was separated by
centrifugation and the supernatant was stored at  201C until use.
For each STS patient, serum samples were obtained 2 days before
surgery and were stored at  801C until assayed. The uPA, uPAR
and PAI-1 antigen content levels in tissue extracts, as well as in
serum of STS patients, were determined applying commercially
available ELISA kits (IMUBIND uPA ELISA # 894, IMUBIND uPAR
ELISA #893 and IMUBIND PAI-1 ELISA 821; American Diagnos-
tica Inc., Stamford, CT, USA) according to the manufacturer’s
instructions. Antigen concentrations in tissue extracts were
expressed in ng analyte per mg of total protein.
Statistical analysis
The levels of significance between continuous variables of
biological markers were calculated using Spearman’s rank
correlation (rs). The relationship of biological marker expression
levels with clinicopathological parameters was evaluated using
non-parametric Mann–Whitney or Kruskal–Wallis tests. For
survival analyses, the OS of STS patients was used as follow-up
end point. The association between biological marker levels and
Table 1 Relationship between biological marker levels in tumour tissue extracts and in serum of STS patients and clinicopathological parameters
Patients’ uPA-T uPAR-T PAI-1-T uPA-S uPAR-S PAI-1-S
characteristics Cases Low/high Low/high Low/high Cases Low/high Low/high Low/high
No. 80 79
Sex
a P¼0.168 P¼0.286 P¼0.981 P¼0.410 P¼0.965 P¼0.369
Male 37 22/15 21/16 18/19 35 18/17 17/18 17/18
Female 43 18/25 19/24 19/21 44 21/23 23/21 23/21
Histological subtype
b Po0.001 Po0.001 P¼0.006 P¼0.286 P¼0.004 P¼0.426
LS 21 18/3 19/2 15/6 20 13/7 15/5 12/8
MFH 17 2/15 3/14 3/14 18 7/11 4/14 9/9
FS 3 2/1 2/1 2/1 3 1/2 2/1 2/1
RMS 6 1/5 1/5 1/5 6 3/3 2/4 3/3
LMS 16 5/11 7/9 10/6 17 7/10 7/10 8/9
NS 5 3/2 1/4 3/2 4 1/3 3/1 2/2
Syn 6 5/1 4/2 4/2 6 3/3 5/1 1/5
Other 6 4/2 3/3 2/4 5 4/1 2/3 3/2
Tumour grade
b Po0.001 Po0.001 Po0.001 P¼0.527 Po0.001 P¼0.839
I 16 14/2 13/3 13/3 16 10/6 13/3 8/8
II 33 20/13 19/14 20/13 32 15/17 18/14 15/17
III 31 6/25 8/23 7/24 31 14/17 9/22 17/14
Tumour stage
b Po0.001 Po0.001 P¼0.006 P¼0.390 P¼0.019 P¼0.713
I 13 11/2 12/1 10/3 13 9/4 10/3 8/5
II 32 20/12 17/15 20/12 31 13/18 19/12 14/17
III 26 5/21 7/19 8/18 26 13/13 8/18 13/13
IV 9 4/5 4/5 2/7 9 4/5 3/6 5/4
Complete resection
a P¼0.644 P¼0.319 P¼0.295 P¼0.699 P¼0.950 P¼0.083
Radical (R0) 54 28/26 29/25 28/26 53 27/26 26/27 25/28
Not radical (R1) 26 12/14 11/15 12/14 26 12/14 14/12 15/11
Localisation
b P¼0.230 P¼0.133 P¼0.038 P¼0.154 P¼0.292 P¼0.836
Extremities 52 26/26 25/27 25/27 51 23/28 25/26 26/25
Trunc wall 6 2/4 3/3 0/6 5 3/2 1/4 2/3
Head/neck 2 0/2 0/2 0/2 2 0/2 0/2 2/0
Abdomen/retro- peritoneum 20 12/18 12/8 15/5 21 13/8 14/7 10/11
Patients follow-up
a P¼0.001 P¼0.004 P¼0.004 P¼0.957 P¼0.013 P¼0.172
Alive 37 24/13 22/15 24/13 37 20/17 23/14 16/21
Dead 43 16/27 18/25 16/27 42 19/23 17/25 24/18
LS¼liposarcoma; MFH¼malignant fibrous histiocytoma; FS¼fibrosarcoma; RMS¼rhabdomyosarcoma; LMS¼leiomyosarcoma; NS¼neurogenic sarcoma; Syn¼synovial
sarcoma; T¼tumour tissue extract; S¼serum; uPA¼urokinase plasminogen activator; STS¼soft-tissue sarcoma.
aP for Mann–Whitney U-test.
bP for Kruskal–Wallis test.
Significant P-values are in bold face.
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and the log-rank test was applied to test for differences. For
multivariate analyses, Cox’s proportional hazard regression model
was used to calculate the relative risk and its 95% confidence
interval (CI) in the analysis of OS. Multivariate models were
adjusted for known clinical prognostic factors in STS patients:
tumour stage, tumour type, type of tumour resection and tumour
localisation. All calculations were performed using the SPSS 17.0
program (SPSS-Science, Chicago, IL, USA). All P-values were
two-sided and Po0.05 was considered statistically significant.
RESULTS
Correlation of uPA, uPAR and PAI-1 levels in tumour
tissue and in serum of STS patients
We investigated the correlation between antigen levels of uPA,
uPAR and PAI-1 in tumour tissue extracts (uPA-T, uPAR-T and
PAI-1-T, respectively) and in serum (uPA-S, uPAR-S and PAI-1-S,
respectively). In tumour tissue extracts, we detected a strong
correlation between uPA-T and uPAR-T (rs¼0.84, Po0.001) or
PAI-1-T (rs¼0.69, Po0.001), and between uPAR-T and PAI-1-T
(rs¼0.83, Po0.001) antigen levels (Table 2). In serum, a moderate
correlation was observed between uPA-S and uPAR-S (rs¼0.54,
Po0.001). However, PAI-1-S values were only weakly, if at all,
correlated with uPA-S (rs¼0.24, Po0.05) or uPAR-S (rs¼0.19,
n.s.) values. Next, we evaluated the relationship between uPA,
uPAR and PAI-1 antigen levels in tumour tissue extracts with that
in serum (Table 2). We found a moderate, significant correlation
between uPAR-S concentration and uPA-T, uPAR-T and PAI-1-T
levels (rs¼0.49, 0.54 and 0.46, respectively, all Po0.001).
Furthermore, the uPA-S concentration was weakly but significantly
correlated with uPA-T, uPAR-T and PAI-1-T values (rs¼0.36, 0.38
and 0.31, respectively, all Po0.01). These results suggest that uPA,
uPAR and PAI-1 levels in the tumour may affect each other or are
regulated in a concerted manner and that they are strikingly
related to the serum levels of uPAR protein in STS patients.
uPA, uPAR and PAI-1 antigen levels in STS tissues and
association with clinical parameters and prognosis
The amount of uPA-T, uPAR-T and PAI-1-T protein has been
determined in 80 STS tissue samples and was related to the whole
protein content in each sample. The median protein expression
for uPA-T was 1.78ngmg
 1 (range: 0–22.76), for uPAR-T
3.98ngmg
 1 (range: 0.17–103.47) and for PAI-1-T, it was
21.43ngmg
 1 (range: 0.57–1,279.0). For statistical analysis, the
median values were used as cutoff points to separate STS patients
into groups with low or high antigen levels in tumour tissue
extracts. The association of uPA-T, uPAR-T and PAI-1-T levels
with relevant clinicopathological factors is summarised in Table 1.
High levels of uPA-T, uPAR-T and PAI-1-T antigen were
significantly associated with histological subtype (Po0.001,
Po0.001 and P¼0.006, respectively), with tumour grade
(Po0.001, Po0.001 and P¼0.001, respectively), and with tumour
stage (Po0.001, Po0.001 and P¼0.006, respectively). Moreover,
uPA-T, uPAR-T and PAI-1-T antigen levels were significantly
higher in patients who died during follow-up time (Table 1).
For survival analysis, the Kaplan–Meier test was performed to
study the effect of uPA-T, uPAR-T and PAI-1-T antigen levels on
prognosis. Overall survival was significantly different between
patients’ groups with high or low antigen levels for all three
markers. Patients with high vs low expression of uPA-T survived
on an average for 44 months vs 86 months (P¼0.003), patients
with high vs low expression of uPAR-T survived on an average for
54 vs 76 months (P¼0.033) and those with high vs low expression
of PAI-1-T survived on an average for 53 vs 79 months (P¼0.004)
(Table 3). The independent relationship of uPA-T, uPAR-T and
PAI-1-T was studied using multivariate Cox’s regression analysis.
For patients whose tumours expressed either a high uPA-T or a
high PAI-1-T antigen level, we detected a significantly, nearly
three-fold increased risk of tumour-related death (RR¼2.9, 95%
CI¼1.1–7.7, P¼0.032; and RR¼2.6, 95% CI¼1.1–6.0, P¼0.029,
respectively) compared with those patients who displayed low
uPA-T or PAI-1-T values in their tumours, respectively (Table 3).
On the other hand, uPAR-T levels did not significantly contribute
to the base model for OS (Table 3). Therefore, only high uPA-T or
PAI-1-T antigen tumour tissue levels are independent prognostic
factors for OS of STS patients.
uPA, uPAR and PAI-1 antigen concentration in serum of
STS patients and association with clinical parameters and
prognosis
The concentration of uPA (uPA-S), uPAR (uPAR-S) and PAI-1
(PAI-1-S) antigen in pre-operative serum samples of 79 STS
patients has been measured by ELISA. We observed a median
antigen concentration of 0.66ngml
 1 (range: 0–4.76) for uPA-S, of
1.60ngml
 1 (range: 0.24–8.03) for uPAR-S and of 1084.0ngml
 1
(range: 44.0–6,068.5) for PAI-1-S. For statistical analysis, the
median values uPA-S, uPAR-S and PAI-1-S were used as cutoff
points to separate STS patients in groups with low or high antigen
concentrations in serum. High concentrations of uPAR-S antigen
were significantly associated with histological subtype (P¼0.004),
tumour grade (Po0.001) and tumour stage (P¼0.019) (Table 1).
On the contrary, uPA-S and PAI-1-S serum antigen levels did not
show any association with clinicopathological features (Table 1).
In Kaplan–Meier analysis, a significantly different OS has been
found between groups of STS patients with high or low uPAR-S
concentrations. Patients with high vs low levels of uPAR-S survived
on an average for 45 months vs 86 months (P¼0.005) (Table 3).
Serum levels of uPA and PAI-1 antigen were not associated with
prognosis of STS patients in univariate analysis (Table 3). In
multivariate Cox’s regression analysis, we found that STS patients
with elevated uPAR-S antigen levels possessed a 3.5-fold increased
risk of tumour-related death (RR¼3.5, 95% CI¼1.5–8.3,
P¼0.004) compared with patients with low uPAR-S concentra-
tions (Table 3).
Combined analysis of uPA, uPAR and PAI-1 antigen levels
for OS
We assessed whether a combination of biological markers might
add prognostic information for patients’ survival. For this analysis,
the patient cohort was divided into four groups on the basis of the
combination of high and low marker values. In Kaplan–Meier
analysis, a co-detection of high levels of uPA-T and PAI-1-T or
uPAR-T, and of PAI-1-T and uPAR-T, was significantly associated
with a shorter OS compared with patients with low antigen levels
of the combined markers in tumour tissue (Table 4). Patients with
high vs low values of uPA-T/uPAR-T survived on an average for 41
vs 75 months (P¼0.007), those with high vs low expression of
uPA-T/PAI-1-T survived on an average for 46 vs 88 months
Table 2 Spearman’s rank correlations between biological parameters
uPA-S uPAR-S PAI-1-S uPA-T uPAR-T
uPAR-S 0.54***
PAI-1-S 0.24* 0.19
uPA-T 0.36** 0.49*** 0.08
uPAR-T 0.38** 0.54*** 0.01 0.84***
PAI-1-T 0.31** 0.46*** 0.04 0.69*** 0.83***
Spearman’s rank correlation rs;* Po0.05; **Po0.01; *** Po0.001.
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uPAR-T survived on an average for 53 vs 86 months (P¼0.014)
(Table 4). In multivariate Cox’s regression analysis, the subgroup
of patients with high uPA-T/uPAR-T, high uPA-T/PAI-1-T or high
uPAR-T/PAI-1-T antigen levels showed the worst OS with RR
values of 3.3 (95% CI¼1.2–9.6, P¼0.026) 3.6 (95% CI¼1.2–10.4,
Table 3 Kaplan–Meier analyses and multivariate Cox’s regression analyses: association of uPA, uPAR and PAI-1 antigen levels in tumour tissue extracts
and in serum of STS patients with overall survival
Kaplan–Meier analysis Multivariate Cox’s regression analysis
n Months P-value RR (95% CI) P-value
Tumour tissue Tumour tissue
uPA high 40 44 0.003 uPA high 2.9 (1.1–7.7) 0.032
uPA low 40 86
uPAR high 40 54 0.033 uPAR high 2.0 (0.8–4.5) 0.108
uPAR low 40 76
PAI-1 high 40 53 0.004 PAI-1 high 2.6 (1.1–6.0) 0.029
PAI-1 low 40 79
Serum Serum
uPA high 40 61 0.467 uPA high 1.2 (0.7–2.3) 0.634
uPA low 39 76
uPAR high 40 45 0.005 uPAR high 3.5 (1.5–8.3) 0.004
uPAR low 39 86
PAI-1 high 40 60 0.336 PAI-1 high 1.4 (0.7–2.8) 0.333
PAI-1 low 39 71
CI¼confidence interval; PAI-1¼urokinase plasminogen activator inhibitor 1; STS¼soft tissue sarcoma; uPA¼urokinase plasminogen activator; uPAR¼urokinase plasminogen
activator receptor. Significant P-values and RR-values are in bold face.
Table 4 Kaplan–Meier analyses and multivariate Cox’s regression analyses for combinations of uPA, uPAR and PAI-1 antigen levels in tumour tissue and
in serum of STS patients and its association with overall survival
Kaplan–Meier analysis n Months P-value Multivariate Cox’s regression analysis RR (95% CI) P-value
uPA-Tumour/uPAR-Tumour 80 uPA-Tumour/uPAR-Tumour
uPA-T low/uPAR-T low 35 75 uPA-T low/uPAR-T low
uPA-T low/uPAR-T high 5 122 uPA-T low/uPAR-T high 0.4 (0.04–3.3) 0.364
uPA-T high/uPAR-T low 5 62 uPA-T high/uPAR-T low 1.4 (0.3–5.9) 0.688
uPA-T high/uPAR-T high 35 41 0.007 uPA-T high/uPAR-T high 3.3 (1.2–9.6) 0.026
uPA-Tumour/PAI-1-Tumour 80 uPA-Tumour/PAI-1-Tumour
uPA-T low/PAI-1-T low 31 88 uPA-T low/PAI-1-T low
uPA-T low/PAI-1-T high 9 54 uPA-T low/PAI-1-T high 2.5 (0.7–9.7) 0.168
uPA-T high/PAI-1-T low 9 36 uPA-T high/PAI-1-T low 2.6 (0.7–9.9) 0.149
uPA-T high/PAI-1-T high 31 46 0.004 uPA-T high/PAI-1-T high 3.6 (1.2–10.4) 0.019
uPAR-Tumour/PAI-1-Tumour 80 uPAR-Tumour/PAI-1-Tumour
uPAR-T low/PAI-1-T low 29 86 uPAR-T low/PAI-1-T low
uPAR-T low/PAI-1-T high 11 39 uPAR-T low/PAI-1-T high 3.0 (1.0–9.2) 0.042
uPAR-T high/PAI-1-T low 11 44 uPAR-T high/PAI-1-T low 2.5 0.7–9.2) 0.173
uPAR-T high/PAI-1-T high 29 53 0.014 uPAR-T high/PAI-1-T high 3.2 (1.1–9.4) 0.034
uPAR-Serum/uPA-Tumour 77 uPAR-Serum/uPA-Tumour
uPAR-S low/uPA-T low 28 94 uPAR-S low/uPA-T low
uPAR-S low/uPA-T high 11 44 uPAR-S low/uPA-T high 4.2 (1.0–17.5) 0.048
uPAR-S high/uPA-T low 10 38 uPAR-S high/uPA-T low 4.9 (1.3–18.0) 0.016
uPAR-S high/uPA-T high 28 44 0.012 uPAR-S high/uPA-T high 5.9 (1.8–19.2) 0.003
uPAR-Serum/uPAR-Tumour 77 uPAR-Serum/uPAR-Tumour
uPAR-S low/uPAR-T low 26 80 uPAR-S low/uPAR-T low
uPAR-S low/uPAR-T high 12 89 uPAR-S low/uPAR-T high 0.9 (0.2–3.9) 0.929
uPAR-S high/uPAR-T low 12 59 uPAR-S high/uPAR-T low 1.9 (0.6–6.6) 0.287
uPAR-S high/uPAR-T high 27 38 0.008 uPAR-S high/uPAR-T high 6.2 (1.9–20.0) 0.002
uPAR-Serum/PAI-Tumour 77 uPAR-Serum/PAI-Tumour
uPAR-S low/PAI-T low 28 82 uPAR-S low/PAI-T low
uPAR-S low/PAI-T high 10 81 uPAR-S low/PAI-T high 1.9 (0.5–6.4) 0.327
uPAR-S high/PAI-T low 11 49 uPAR-S high/PAI-T low 2.6 (0.8–8.9) 0.115
uPAR-S high/PAI-T high 28 39 0.007 uPAR-S high/PAI-T high 5.8 (1.9–17.0) 0.001
CI¼confidence interval; PAI-1¼urokinase plasminogen activator inhibitor 1; STS¼soft-tissue sarcoma; uPA¼urokinase plasminogen activator; uPAR¼urokinase plasminogen
activator receptor. Significant P-values and RR-values are in bold face.
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compared with patients having tumours with low values for both
markers (Table 4).
Furthermore, the effect of uPA, PAI-1 or uPAR antigen levels in
tumour tissue, in combination with the uPAR antigen concentra-
tion in serum on OS, was studied. In univariate Kaplan–Meier
analysis, OS was significantly different between patient subgroups,
with high values of combined markers vs low values for all three
marker combinations, i.e., patients with high vs low levels of
uPA-T/uPAR-S survived on an average for 44 months vs 94 months
(P¼0.012), those with high vs low levels of uPAR-T/uPAR-S on an
average for 38 vs 80 months (P¼0.008) and those patients with
high vs low levels of PAI-1-T/uPAR-S on an average for 39 vs 82
months (P¼0.007) (Table 4).
In multivariate Cox’s regression analysis, we found for the
subgroups of patients with a high uPA-T/uPAR-S, a high uPAR-T/
uPAR-S or a high PAI-1-T/uPAR-S, an B6-fold significantly
increased risk of tumour-related death (RR¼5.9, 95% CI¼1.8–
19.2, P¼0.003; RR¼6.2, 95% CI¼1.9–20.0, P¼0.002; RR¼5.8,
95% CI¼1.9–17.0, P¼0.001, respectively) compared with those
patients who showed low values for each marker combination
(Table 4, Figure 1). Thus, there is an additional effect on prognosis
when uPA, PAI-1 and uPAR levels in tumour tissue were
combined, which is even more pronounced for the combination
of uPA, PAI-1 and uPAR tissue levels with uPAR serum values.
DISCUSSION
The uPA system is one of the best-investigated protease systems
under both physiological and pathological conditions, including
various types of cancer (Duffy et al, 2008).
There are many studies investigating the clinical impact of
expression of members of the uPA system and its correlation to
prognosis in carcinoma (Duffy and Duggan 2004; McMahon and
Kwaan, 2007–08; Duffy et al. 2008) but so far only one study has
been conducted for STS patients (Choong et al, 1996). Choong et al
(1996) detected an association of increasing uPA protein levels in
tumour tissue with local recurrence and metastasis in 69 STS
patients. In our study, single protein levels of uPA and PAI-1, and
combined protein levels of uPA, uPAR and PAI-1, in tumour
tissues were significantly correlated with an up to 3.6-fold
increased risk of tumour-related death. There are two main
reasons for a clinical impact of expression of uPA, uPAR and PAI-1
in tumour tissues and their correlation with prognosis. First, the
uPA system has a role in modulating cell adhesion, overcoming
ECM boundaries and can interact with potential oncogenes. The
binding of uPA to membrane-bound uPAR results in focusing
active uPA to cells, and in efficient cell-associated cleavage of
plasminogen to plasmin, which subsequently breaks down ECM
and facilitates cancer invasion (Clark et al, 2008). On one hand,
uPAR concentrates uPA enzymatic activity to the tumour cell, on
the other, there is also a mutual cooperation between uPAR and
further interactors: the activity of integrins, chemokines, cytokines
and growth factor receptors (Ragno, 2006; Tang and Wei, 2008).
Furthermore, in cancer cells, Ras signalling is linked to the uPA
system (Silberman et al, 1997). Second, the uPA system has a role
in overcoming tissue boundaries. Recently, a physiological role for
uPAR signalling in the regulation of kidney permeability has been
described (Wei et al, 2008). Another study investigating the entry
of fibrosarcoma cells into the vasculature (i.e., intravasation)
points to the same direction. After inhibition of uPA by natural or
synthetic inhibitors in the chorioallantoic membrane of chick
embryos, both inhibitors reduced intravasation and metastasis.
The authors suggest uPA activation as a key step in tumour
progression (Madsen et al, 2006). The effects of members of the
uPA system on tumour cell biology, cell migration and metastases
can be reversed in in vivo models. Mice with a targeted deficiency
for uPA or PAI-1 showed a significantly reduced tumour growth
after transplantation of fibrosarcoma cells. Tumours in uPA / 
and PAI-1 /  mice displayed lower proliferative and higher
apoptotic indices and displayed different neovascular morphology,
as compared with WT mice (Gutierrez et al, 2000). In line with
these results are findings in a mouse osteosarcoma model. In this
in vivo model of tibial tumours, uPAR mRNA was expressed early
(4 days), whereas uPA and PAI-1 mRNA increased as the tumour
invaded the surrounding tissue (3 weeks). Interestingly, there was
a preferential co-localisation of uPA, uPAR and PAI-1 mRNA to
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Figure 1 Multivariate Cox’s regression hazard analysis: association of
combined marker levels with overall survival of STS patients. (A)
Combined values of uPAR antigen in serum and uPA antigen in tumour
tissue extracts. (B) Combined values of uPAR antigen in serum and PAI-1
antigen in tumour tissue extracts. (C) Combined values of uPAR antigen in
serum and in tumour tissue extracts. Patients with high expression of uPAR
antigen levels in serum and with high levels of uPA (A), PAI-1 (B) or uPAR
(C) in tumour tissue extracts possessed a 5.9-, 5.8- or 6.2-fold increased
risk of tumour-related death compared with patients who showed a low
concentration for both proteins.
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Furthermore, injection of an antisense uPAR inhibitor resulted
in a significant reduction in tumour volumes and in total
inhibition of pulmonary metastases (Dass et al, 2005). In another
mouse model, treatment with a uPAR antibody and a recombinant
pigment epithelium-derived factor that may internalise uPA/uPAR
complexes led to decreased ostoeosarcoma growth and metastasis
(Dass and Choong 2008).
A few studies have analysed uPA and PAI-1 antigen levels in
plasma/serum and its contribution to prognosis in carcinoma
patients but none have been conducted for sarcoma patients
(Strojan et al, 1998; Miyake et al, 1999; Abendstein et al, 2000; Rha
et al, 2000; Shariat et al, 2007; Iwadate et al, 2008; Hersze ´nyi et al,
2008). Strikingly, in our study, uPAR antigen levels in serum of
STS patients were found to be highly and significantly associated
with poor OS in Kaplan–Meier analyses and in multivariate Cox’s
regression analyses. This is in line with other studies that reported
that high serum levels of soluble uPAR (suPAR) were significantly
associated with worse survival in colorectal, prostate, ovarian and
breast cancer, as well as in multiple myeloma (Sier et al, 1998;
Bru ¨nner et al, 1999; Miyake et al, 1999; Stephens et al, 1999;
Riisbro et al, 2002; Rigolin et al, 2003; Shariat et al, 2007) In
contrast to cell-bound uPAR, which focuses uPA mediated plasmin
formation to the cell surface, the role and source of suPAR remain
to be clarified (Bru ¨nner et al, 1999). Holst-Hansen et al (1999)
demonstrated that the amount of suPAR released from breast
cancer cell lines was directly correlated to the number of viable
cells. In addition, using a breast cancer xenograft tumour model,
the authors demonstrated that the concentration of suPAR in
plasma was highly correlated with tumour volume. Furthermore,
Shariat et al (2007) found a direct association between high suPAR
levels in serum and tumour burden in prostate cancer, and its
decrease after tumour removal. Overall, these studies suggest that
local expression/production of uPAR on tumour cells may
significantly contribute to the increased levels of suPAR levels in
serum of cancer patients. In our study, we observed a relatively
high correlation between uPAR antigen levels in tumour tissue and
serum (rs¼0.54), which may indicate that suPAR levels, at least
partially, derive from cancer cells. In a recent study, Riisbro et al
(2002) did not find a correlation between uPAR levels in breast
cancer tissue with that in serum of breast cancer patients, and
whereas uPAR levels in serum were significantly associated with
worse prognosis of breast cancer patients, uPAR levels in tumour
cytosols were not. However, Meng et al (2006) reported that the
uPAR gene status – contributing to uPAR overexpression – in
breast cancer cells from blood and tumour tissue is concordant.
Therefore, besides cell-bound uPAR that is shed from primary
tumour tissue, other sources of suPAR should also be considered,
such as blood monocytes or neutrophile granulocytes that may
become activated due a systemic reaction to tumour growth/
progression (Shariat et al, 2007), or as an association with
circulating tumour cells (Mustjoki et al, 2000). Correlation of
uPAR levels in serum with prognosis of STS patients could
improve cancer detection and monitoring of cancer progression, as
investigation of serum samples is more easily performed than that
of cancer tissues, which is limited by tumour size, tumour
heterogeneity and freezing capacities.
Most strikingly, combined high levels of uPA, uPAR and PAI-1
in tumour tissue and of uPAR in serum were found to be
correlated with an additive negative effect on prognosis. However,
further possibilities of affecting tumour spread and formation of
metastases could be the role of the uPA system in haemostasis, as
well as in inflammatory and immune processes (Mondino and
Blasi, 2004). Finally, the uPA system might facilitate the
recruitment of tumour cells and tumour-associated cells at the
sites of metastasis using these processes.
In conclusion, co-detection of a high expression level of these
uPA system members in tumour tissue and of uPAR in serum is
significantly correlated with a shortened OS of STS patients,
suggesting that protein expression in tumour tissue and in serum
should be considered together for prognostic evaluation.
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